Outbound M&A fuels IPO pipeline

摘要

Hong Kong's IPO market is emerging as a beneficiary of the recent surge in outbound Chinese acquisitions as mainland companies look to monetise their investments. French medical devices maker ECHOSENS, owned by Shenzhen-listed Inner Mongolia Furui Medical Science, started premarketing a US$100m IPO last week. Shanghai Fosun Pharmaceutical is also mulling a US$100m-$200m listing of Israeli subsidiary SISRAM MEDICAL in the summer. Echosens and Sisram are part of an early wave of overseas acquisitions from China, and their listings suggest the Hong Kong equity-market is in store for a boost as companies look to cash in on more recent purchases.